ENVB · NASDAQ
Enveric Biosciences (ENVB) Stock Price & Fundamentals
Enveric Biosciences (ENVB) closed at $619.16 on Oct 9, 2026, down 0.58% from the previous close of $622.75.
Share price, past year
1Y +13.60%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $619.16 |
| Sep 30, 2026 | $608.11 |
| Aug 31, 2026 | $610.63 |
| Jul 31, 2026 | $622.16 |
| Jun 30, 2026 | $602.80 |
| May 29, 2026 | $610.67 |
| Apr 30, 2026 | $586.03 |
| Mar 31, 2026 | $584.96 |
| Feb 27, 2026 | $585.91 |
| Jan 30, 2026 | $588.80 |
| Dec 31, 2025 | $578.80 |
| Nov 28, 2025 | $550.77 |
| Oct 31, 2025 | $547.18 |
Key statistics
- Market cap
- $2.44B
- P/E (TTM)
- —
- EPS (TTM)
- −$11.85
- Revenue (TTM)
- —
- Net income (TTM)
- −$8.73M
- Shares outstanding
- 3.9M
- Dividend yield
- —
- 52-week range
- $527.93 – $627.25
Enveric Biosciences's market cap is $2.44B, based on a share price of $619.16 and 3.9M shares outstanding as of Jun 30, 2026.
Financials
Enveric Biosciences reported revenue of $39.91M for fiscal 2019, down 7.17% from fiscal 2018.
Enveric Biosciences reported a net loss of $8.77M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2019ended Dec 31, 2019 | $39.91M | −7.2% | −$2.41M | −6.0% | −$2.83 | — |
| FY2018ended Dec 31, 2018 | $43.00M | −11.5% | −$16.90M | −39.3% | −$20.47 | — |
| FY2017ended Dec 31, 2017 | $48.59M | +34.4% | −$9.07M | −18.7% | −$18.75 | — |
| FY2016ended Dec 31, 2016 | $36.15M | +78.4% | −$2.78M | −7.7% | −$5.25 | — |
| FY2015ended Dec 31, 2015 | $20.26M | — | — | — | — | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q3 FY2020ended Sep 30, 2020 | $8.48M | — | — |
| Q2 FY2020ended Jun 30, 2020 | $8.25M | — | — |
| Q1 FY2020ended Mar 31, 2020 | $9.60M | — | — |
| Q4 FY2019ended Dec 31, 2019 | $9.06M | — | — |
| Q3 FY2019ended Sep 30, 2019 | $9.15M | — | — |
| Q2 FY2019ended Jun 30, 2019 | $11.02M | — | — |
| Q1 FY2019ended Mar 31, 2019 | $10.69M | — | — |
| Q4 FY2018ended Dec 31, 2018 | $10.28M | — | — |
Company profile
- Name
- Enveric Biosciences, Inc.
- Ticker
- ENVB
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 245 First Street Riverview Ii 18th Floor, Cambridge, MA 02142
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0000890821
Recent SEC filings
- Aug 14, 2026
- Aug 14, 2026
- Jun 9, 2026
- Jun 9, 2026
- May 29, 2026
- May 15, 2026
- May 15, 2026
- Apr 30, 2026
Frequently asked questions
What is Enveric Biosciences's stock price?
Enveric Biosciences (ENVB) closed at $619.16 on Oct 9, 2026, down 0.58% from the previous close of $622.75.
What is Enveric Biosciences's market cap?
Enveric Biosciences's market cap is $2.44B, based on a share price of $619.16 and 3.9M shares outstanding as of Jun 30, 2026.
How much revenue does Enveric Biosciences make?
Enveric Biosciences reported revenue of $39.91M for fiscal 2019, down 7.17% from fiscal 2018.
Does Enveric Biosciences pay a dividend?
Enveric Biosciences's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Enveric Biosciences, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures